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Objective: To determine whether overexpression of cell membrane associated drug efflux pumps
belonging to the family of ATP binding cassette (ABC) proteins contributes to a diminished efficacy of
sulfasalazine (SSZ) after prolonged cellular exposure to this disease modifying antirheumatic drug
(DMARD).
Methods: A model system of human T cells (CEM) was used to expose cells in vitro to increasing
concentrations of SSZ for a period of six months. Cells were then characterised for the expression of drug
efflux pumps: P-glycoprotein (Pgp, ABCB1), multidrug resistance protein 1 (MRP1, ABCC1), and breast
cancer resistance protein (BCRP, ABCG2).
Results: Prolonged exposure of CEM cells to SSZ provoked resistance to SSZ as manifested by a 6.4-fold
diminished antiproliferative effect of SSZ compared with parental CEM cells. CEM cells resistant to SSZ
(CEM/SSZ) showed a marked induction of ABCG2/BCRP, Pgp expression was not detectable, while MRP1
expression was even down regulated. A functional role of ABCG2 in SSZ resistance was demonstrated by
60% reversal of SSZ resistance by the ABCG2 blocker Ko143. Release of the proinflammatory cytokine
tumour necrosis factor a (TNFa) was threefold higher in CEM/SSZ cells than in CEM cells. Moreover,
twofold higher concentrations of SSZ were required to inhibit TNFa release from CEM/SSZ cells compared
with CEM cells.
Conclusion: Collectively, ABCG2 induction, augmented TNFa release, and less efficient inhibition of TNFa
production by SSZ may contribute to diminished efficacy after prolonged exposure to SSZ. These results
warrant further clinical studies to verify whether drug efflux pumps, originally identified for their roles in
cytostatic drug resistance, can also be induced by SSZ or other DMARDs.
S
ulfasalazine (SSZ) is a widely applied disease modifying
antirheumatic drug (DMARD), either as a single agent
or in combination with other DMARDs.1–5 The anti-
inflammatory properties of SSZ have been attributed to
diminished production of proinflammatory cytokines such as
tumour necrosis factor a (TNFa) through multiple mechan-
isms, including (a) inhibition of the activation of nuclear
factor kappa B (NFkB) by inhibition of inhibitor kappa B
kinase (IKK)6 7; (b) inhibition of the purine biosynthesis de
novo enzyme 5-aminoimidazole-4-carboxamidoribonucleo-
tide transformylase8 9; and (c) induction of apoptosis in
lymphocytes and macrophages.10 11
In clinical practice the median duration of use of SSZ is 1–2
years.12 A meta-analysis of DMARD treatment termination
rates based on 159 studies showed that after initial activity,
most withdrawals of SSZ resulted from the lack of efficacy
rather than toxicity.13 The underlying mechanism(s) for this
lack of efficacy has not been established. Given the long term
DMARD treatment patients with rheumatoid arthritis (RA)
receive, we rationalised that the onset of acquired drug
resistance to SSZ, analogous to resistance to anticancer drugs
or anti-infectious drugs,14–16 might contribute to its lack of
efficacy. From an anti-inflammatory perspective, drug
resistance may refer to a diminished ability of DMARDs to
inhibit secretion of proinflammatory cytokines by inflamma-
tory cells. Mechanistically, this can be provoked by either
augmented basal levels of cytokine secretion or, indirectly,
through attenuated antiproliferative/apoptotic effects of
DMARDs. Diminished antiproliferative effects mediated by
overexpression of specific energy (ATP) dependent drug
efflux pumps are a common and established mechanism of
resistance to anticancer drugs. These drug efflux pumps
belong to a superfamily of ATP binding cassette (ABC)
transporters.17–19 ABC transporters with an established role in
drug resistance include: P-glycoprotein (Pgp/ABCB1),20
multidrug resistance associated proteins 1–5 (MRP1–5/
ABCC1–5),21 22 and breast cancer resistance protein (BCRP/
ABCG2).15 23 Currently, very little is known about SSZ as a
potential substrate for one or more of the different MDR
pumps or other transporters.24 On the basis of its chemical
structure as an organic anion, SSZ may belong to a class of
compounds transported by the drug efflux pump MRP1 that
has a preferred substrate affinity for anionic (glutathione
conjugated) compounds.19 22
To gain insight from a rheumatological perspective into
possible mechanism(s) of resistance to the antiproliferative/
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anti-inflammatory effects of SSZ, we provoked acquired
resistance to SSZ in an in vitro model system for human T
cells (CEM) by stepwise exposure of CEM (T) cells to
gradually increasing concentrations of SSZ.
In this study we observed that SSZ resistance in CEM (T)
cells was conferred by overexpression of a drug efflux pump,
the multidrug resistance transporter BCRP/ABCG2.
Consistent with reduced drug uptake, inhibition of nuclear
NFkB activity in SSZ resistant cells, as reflected by TNFa
production, required at least twofold higher SSZ concentra-
tions as compared with CEM (T) cells.
MATERIALS AND METHODS
Materials
Sulfasalazine, 59-aminosalicylic acid, sulfapyridine, phorbol
12-myristate 13-acetate (PMA), ionomycin, verapamil, and
phenylmethylsulfonyl fluoride (PMSF) were purchased from
Sigma Chemical Co (St Louis, MO, USA). Protease inhibitor
cocktail (PIC) and Triton X-100 were from Boehringer
Mannheim (Ingelheim, Germany). The ABCG2 inhibitor
Ko14325 was kindly provided by Dr A Schinkel (Netherlands
Cancer Institute, Amsterdam, The Netherlands). The MRP1
blocker MK571 was provided by Merck Frosst, Quebec,
Canada. RPMI-1640 tissue culture medium and fetal calf
serum (FCS) were obtained from Gibco Chemical Co, Grand
Island, NY, USA.
Selection of SSZ resistance in CEM (T) cells
In this study human CEM T lineage lymphocytic cells were
used as a model system for human T cells. CEM (T) cells were
originally isolated by Foley et al26 and characterised by several
T cell marker molecules, including CD3, CD4, CD8, and
CD25.27 CEM (T) cells have been employed as a representative
model to study resistance mechanisms for DMARDs like
methotrexate.28–30 CEM (T) cells were cultured at an initial
density of 36105 cells/ml in RPMI-1640 medium supplemen-
ted with 10% FCS, 2 mM L-glutamine, and 100 mg/ml
penicillin and streptomycin in a 5% CO2 incubator at 37 C˚
as described previously.31 Cell cultures were refreshed twice
weekly. SSZ was added to the suspension culture of CEM (T)
cells at an initial concentration of 0.4 mmol/l (IC50 concen-
tration). When cell growth in SSZ-containing medium
approximated growth of control CEM (T) cells, SSZ concen-
trations in the medium were stepwise increased by 0.1–
0.2 mmol/l. After a period of 4–6 months SSZ resistant CEM
(T) cells selected at 1.5 mM SSZ (CEM/SSZ1.5) and 2.5 mM
SSZ (CEM/SSZ2.5) were used for further characterisation.
Antiproliferative effects of SSZ were analysed by plating
1.256105 cells/ml in individual wells of a 24 well plate
containing up to 50 ml of SSZ solutions. Inhibition of cell
growth was determined after 72 hours’ incubation by
counting viable cells on the basis of trypan blue exclusion.
The SSZ concentration required to inhibit cell growth by 50%
compared with control growth is defined as the IC50
concentration.
Nuclear fractionation
Ten million CEM (T) and CEM/SSZ1.5 cells were harvested
and washed three times with 25 ml ice cold Hepes buffered
saline (pH 7.4). All further experiments were carried out at
4 C˚. The final cell pellet was suspended in 0.5 ml buffer A
(10 mM Hepes, 1.5 mM MgCl2, 10 mM KCl, 1 mM dithio-
threitol (DTT), 1 mM PMSF, pH 7.9) and centrifuged (five
minutes, 1200 rpm). The pellet was resuspended in 80 ml of
buffer A supplemented with 0.1% Triton X-100 and 3 ml PIC
(one tablet/ml H2O). After 10 minutes at 4 C˚ the suspension
was centrifuged (five minutes, 1200 rpm) and the pellet was
washed once with 0.5 ml buffer A and centrifuged (five
minutes 1200 rpm). The pellet was carefully resuspended in
70 ml buffer B (20 mM Hepes, 25% (vol/vol) glycerol, 0.42 M
NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 1 mM DTT, 1 mM
PMSF, and 3 ml PIC, pH 7.9) to allow lysis of the nuclear
membrane. After 30 minutes’ incubation the extract was
centrifuged in an Eppendorf microcentrifuge (20 minutes,
14 000 rpm, 4 C˚). Aliquots of the nuclear extracts were
sampled for protein content (Biorad assay), the remainder
was stored at 280 C˚ for NFkB p65 western blotting.
Western blotting
For analysis of expression of Pgp, MRP1, and BCRP/ABCG2
cells were harvested in the mid-log phase of growth and
washed three times with ice cold Hepes buffered saline,
pH 7.4. Total cell lysates of 107 cells were prepared by
suspending them in 500 ml of lysis buffer containing 50 mM
Tris-HCl (pH 7.6), 5 mM DTT, 20 ml PIC (one tablet/ml H2O),
20% glycerol, and 0.5% NP-40. The suspension was sonicated
(MSE sonicator, amplitude 6, for 365 seconds with 30 sec-
ond time intervals at 4 C˚) and centrifuged in an Eppendorf
microcentrifuge (10 minutes, 14 000 rpm, 4 C˚). Protein con-
tent of the supernatant was determined by Biorad protein
assay. Fifty microgram of total cell lysates was fractionated
on a 7.5% polyacrylamide gel and transferred onto a
nitrocellulose membrane. The nitrocellulose membranes were
preincubated overnight at 4 C˚ in blocking buffer (5% Biorad
Blocker in TBS-T (10 mM Tris-HCl, pH 8.0, 0.15 M NaCl,
0.1% Tween-20) to prevent a specific antibody binding. After
blocking, the membranes were incubated for one hour at
room temperature with the primary antibodies for Pgp (JSB1,
1:500), MRP1 (MRPr1, 1:500) or ABCG2/BCRP (BXP21,
1:400) as described by Scheffer et al.32 33 As control for
loading b-actin was used (MAB1501R, 1:3000, Chemicon
International, Ca, USA). After three washing steps with TBS-
T, the membrane was incubated for one hour with horse-
radish peroxidase labelled antirat/mouse (1:2000, Dako) as
secondary antibody. Detection of the antibody binding was
measured by enhanced chemiluminescence (ECL) according
to the manufacturer’s instructions (Amersham International,
Buckinghamshire, UK). Protein levels were determined by
densitometric scanning (GelDoc and Molecular Analyst,
Biorad Laboratories) of the x ray films (Hyperfim ECL,
Amersham International, Buckinghamshire, UK).
For analysis of the presence of the p65 subunit of NFkB in
the nucleus, 30 mg of nuclear protein was fractionated on a
7.5% polyacrylamide gel, transferred to nitrocellulose mem-
branes, and probed with NFkB p65 antibody (Santa Cruz,
sc8008, 1:2000) before ECL detection as described above.
TNFa ELISA
TNFa production was analysed after stimulation of CEM (T)
and CEM/SSZ cells (36105/ml) for 24 hours with PMA
(10 ng/ml)/ionomycin (1 mM). After this period supernatants
were collected by centrifugation (five minutes, 3000 rpm)
and analysed for TNFa by enzyme linked immunosorbent
assay (ELISA; Central Laboratory of Blood Transfusion,
Amsterdam) according to the manufacturer’s instruction.
The detection limit of the TNFa ELISA was 5 pg/ml.
Statistical analysis
Statistical significance of differences was analysed by
Student’s t test. A p value ,0.05 was considered to be
significantly different.
RESULTS
Onset of SSZ resistance in CEM (T) cells
To investigate whether CEM (T) cells developed over time
less sensitivity to SSZ, CEM (T) cells were continuously
exposed in vitro to stepwise increasing concentrations of
SSZ. After a period of 4–6 months’ culture, CEM (T) cells
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could be maintained in SSZ concentrations that exceeded
3.5–6-fold the initially selected SSZ concentration of
0.4 mM SSZ (fig 1A). Cells selected at an intermediate
level of resistance (1.5 mM SSZ) and a final level of 2.5 mM
SSZ were used for further characterisation. Figure 1B shows
the antiproliferative effect of SSZ against CEM (T), CEM/
SSZ1.5, and CEM/SSZ2.5 cells. Concentrations of SSZ
required for 50% growth inhibition were 4.3-fold (p,0.001)
and 6.4-fold (p,0.001) higher for CEM/SSZ1.5 (IC50 1.72
(0.17) mM) and CEM/SSZ2.5 cells (IC50 2.55 (0.21) mM),
respectively, as compared with CEM (T) cells (IC50 0.40
(0.03) mM).
Because in vivo SSZ can be catabolised into two com-
ponents, that is 59-aminosalicylic acid (59-ASA) and sulfa-
pyridine (SP),34 we analysed whether one or both of these
components might contribute to the SSZ resistant
phenotype. It was noted that neither 59-ASA nor SP, either
separately or combined, displayed an antiproliferative effect
at equimolar concentrations of intact SSZ (results not
shown).
These results indicate that human CEM (T) cells can
develop resistance to SSZ upon long term exposure to this
DMARD. Resistance to SSZ does not involve its in vivo
catabolites 59-ASA and SP.
Expression of multidrug resistance transporters in
CEM (T) and CEM/SSZ cells
Because SSZ is an organic anion that might be a potential
substrate for ATP driven drug efflux pumps, we investigated
whether SSZ resistance in CEM (T) cells was mediated by up
regulated expression of one or more of the major MDR
transporters Pgp, MRP1, or ABCG2 (BCRP). CEM/SSZ1.5
cells and CEM/SSZ2.5 cells displayed a marked up regulation
of ABCG2 compared with CEM (T) cells, in which ABCG2
expression was negligible (fig 2A). In contrast, control levels
of MRP1 expression in CEM (T) cells were down regulated in
CEM/SSZ1.5 and CEM/SSZ2.5 cells compared with CEM (T)
cells. Along with Pgp, other MDR related molecules pumps
(MRP2, MRP3, and LRP35) also were undetectable in CEM
(T), CEM/SSZ1.5, and CEM/SSZ2.5 cells (not shown). These
results demonstrate that the drug resistance efflux pump
ABCG2 is markedly up regulated during acquired resistance
of CEM (T) cells to SSZ.
Reversal of ABCG2/BCRP mediated SSZ resistance in
CEM/SSZ cells
To establish whether ABCG2/BCRP is functionally active in
conferring resistance to SSZ, BCRP was blocked by a specific
inhibitor, Ko143,25 to verify reversal of resistance. Blocking of
ABCG2/BCRP reversed SSZ resistance by 50–60%, but not
completely to CEM (T) cell sensitivity (fig 2B). Blockers of
MRP1 (MK571) or Pgp (verapamil) did not reverse SSZ
resistance. These results demonstrate that ABCG2 has a
functional role in conferring resistance to SSZ.
TNFa production and nuclear NFkB p65 expression in
CEM (T) and CEM/SSZ cells
SSZ is a potent inhibitor of the production of the pro-
inflammatory cytokine TNFa by inhibiting the nuclear
activation of the transcription factor NFkB.6 36 To assess
whether SSZ resistance affected production of TNFa, secre-
tion of this cytokine was determined for CEM (T) and CEM/
SSZ cells after 24 hours’ PMA/ionomycin stimulation in the
absence or presence of a concentration range of SSZ (fig 3A).
The basal level of TNFa production by CEM/SSZ1.5 and CEM/
SS2.5 cells was markedly increased (2.0-fold (p,0.001) and
2.9-fold (p,0.001), respectively) compared with CEM (T)
cells. Beyond this, twofold higher concentrations of SSZ were
required to inhibit TNFa production by 50% in CEM/SSZ1.5
cells (IC50 0.95 mM) and CEM/SSZ2.5 cells (IC50 1.1 mM)
compared with CEM (T) cells (IC50 0.55 mM). Consequently,
the area under the curve of TNFa production measured over
the range of SSZ concentrations (fig 3A) was 2.5-fold and
4.6-fold greater for CEM/SSZ1.5 and CEM/SSZ2.5 cells,
respectively, compared with CEM (T) cells.
Because the mechanistic basis of SSZ to inhibit TNFa
production is by preventing the cytosolic to nuclear trans-
location of the nuclear transcription factor NFkB,6 36 we
analysed whether increased nuclear NFkB levels themselves
and/or an impaired potency of SSZ to reduce nuclear NFkB
expression could explain the observed differences in absolute
TNFa production and the diminished inhibitory effect of SSZ
on TNFa production for CEM/SSZ2.5 cells compared with
CEM (T) cells. At the time of TNFa analysis, after 24 hours’
PMA/ionomycin stimulation, expression of the nuclear NFkB
p65 subunit was determined in CEM (T) cells and CEM/
SSZ1.5 cells in the absence or presence of SSZ. Unstimulated
CEM (T) cells and CEM/SSZ1.5 cells did not appear to differ
Figure 1 (A) Onset of SSZ resistance in human CEM (T) cells. SSZ resistance was provoked by culturing CEM (T) cells in stepwise increasing
concentrations SSZ over time. (B) SSZ sensitivity for CEM (T) cells, CEM/SSZ1.5, and CEM/SSZ2.5 cells. Antiproliferative effects were assessed after
72 hours’ exposure to SSZ. Results are the mean of 3–5 separate experiments (SD ,20%).
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in their basal level of nuclear NFkB p65 expression (fig 3B,
lanes A v E). SSZ exposure to CEM (T) cells resulted in a
markedly decreased nuclear NFkB p65 expression, both in
unstimulated cells (lanes A v B) or after PMA/ionomycin
exposure (lanes C v D). In contrast, SSZ exposure had little
effect on nuclear NFkB p65 expression in either unstimulated
CEM/SSZ1.5 cells (lanes E v F) or PMA/ionomycin stimulated
CEM/SSZ1.5 cells (lanes G v H). Similar results were observed
for CEM/SSZ2.5 cells (results not shown). Together, these
results suggest that owing to ABCG2 mediated efflux, SSZ is
less effective in inhibiting nuclear NFkB p65 activation in
CEM/SSZ cells than in CEM (T) cells.
DISCUSSION
As far as we know this study is the first report to show that
long term exposure of human T cells to the DMARD
sulfasalazine can lead to development of resistance by
induction of a drug efflux pump, the MDR transporter
BCRP/ABCG2. Reduced intracellular drug levels not only led
to impaired antiproliferative effects but also to a less effective
inhibition of nuclear NFkB activation by SSZ in the resistant
cells. Thus, SSZ resistant cells required more SSZ to inhibit
TNFa secretion.
Development of drug resistance is a common cause of
treatment failure for anticancer drugs or antimalarial
drugs.16 37 Drug resistance to DMARDs has received little
attention in rheumatology even though loss of efficacy for
several DMARDs, including SSZ, is well established upon
long term treatment.12 13 In this study we mimicked the onset
of SSZ resistance by exposing human CEM (T) cells in vitro to
stepwise increasing concentrations of SSZ. Interestingly, SSZ
resistance was associated with an up regulated expression of
a recently discovered MDR transporter, BCRP, originally
discovered in breast cancer cells selected for resistance (loss
Figure 2 (A) Expression of MDR transporters Pgp, MRP1, and ABCG2/BCRP in CEM (T) and CEM/SSZ1.5 cells. Western blots were performed using
total cell lysates of CEM (T) and CEM/SSZ1.5 cells. Cell lysates of CEM/VBL100,64 2008/MRP1,32 and MCF7/MR40 served as positive control for Pgp,
MRP1, and ABCG2, respectively. For CEM (T) and CEM/SSZ1.5 cells, 50 mg of cell lysate was applied on the sodium dodecyl sulphate-polyacrylamide
gel, and for the controls 10 mg protein. Pgp was detected by the monoclonal antibody JSB1, MRP1 was detected by the monoclonal antibody MRPr1,
and ABCG2 was detected by the monoclonal antibody BXP21.32 33 (B) Reversal of SSZ resistance in CEM/SSZ1.5 cells by ABCG2 blocker Ko143, but
not by Pgp blocker verapamil or MRP1 blocker MK571. CEM/SSZ1.5 cells were incubated in medium containing non-toxic concentrations of the
ABCG2 blocker Ko143 (0.5 mM), MRP1 blocker MK571 (20 mM), or Pgp blocker verapamil (10 mM) and evaluated for SSZ sensitivity compared with
parental CEM (T) cells as described in fig 1B. Results are presented as the mean of three experiments (SD ,20%).
Figure 3 (A) TNFa production by CEM (T), CEM/SSZ1.5, and CEM/SSZ2.5 cells (36105/ml) after 24 hours’ stimulation with PMA/ionomycin in the
absence or presence of a concentration range of SSZ. TNFa levels were determined by ELISA. Results are mean (SD) of 5–7 separate experiments. (B)
NFkB p65 expression in nuclear extracts of CEM (T) cells and CEM/SSZ1.5 cells after 24 hours’ stimulation with PMA/ionomycin in the absence or
presence of SSZ (1.0 mM).
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of antiproliferative effects) to the anticancer agents mitox-
antrone and doxorubicin.38–41 Tissue distribution studies
demonstrated that ABCG2/BCRP expression is not restricted
to breast cancer tissues. ABCG2 is expressed in a limited
number of normal tissues (liver, colon epithelium, mammary
gland, and blood vessels).33 Expression of ABCG2 in synovial
cells and tissues has not been explored. Very recently, ABCG2
expression was described in blood cells, notably CD34+
haematopoietic progenitor cells42 and in acute myeloid
leukaemia cells.43 44 The physiological function of BCRP/
ABCG2 is as yet unknown, although recent studies with
BCRP2/2 knockout mice indicated a crucial role in the
cellular extrusion and detoxification of dietary phototoxins.45
In our study, evidence for a functionally active ABCG2 drug
efflux pump in CEM/SSZ cells was demonstrated by the fact
that Ko143,25 a blocker of BCRP/ABCG2, could reverse
resistance to SSZ. In addition, CEM/SSZ displayed cross
resistance and reversal by Ko143 to mitoxantrone,39 a
prototypical substrate for ABCG2.45a
The observation that the antirheumatic drug SSZ, like
distinct anticancer drugs, can induce up regulation of ABCG2
expression may imply that these drugs share a common
target that triggers a response of ABCG2 up regulation.
Unlike the ABC transporter Pgp,46 there is no evidence for a
direct transcriptional regulation of ABCG2 via an NFkB
binding site on the ABCG2 promoter.47 However, most drugs
involved in ABCG2 up regulation, mitoxantrone,48 doxorubi-
cin,49 daunorubicin,50 CPT-11/SN38,49 51 and flavopiridol,52
have all been documented to target the NFkB signalling
pathway by activating NFkB and stimulating IKBa degrada-
tion. Together, these results suggest that sustained (danger)
signals mediated through the NFkB signalling pathway may
provoke up regulation of drug efflux pumps like ABCG2.
Along with the loss of antiproliferative effects of SSZ
against CEM/SSZ cells (fig 1B), a diminished anti-inflam-
matory effect was also noted as markedly higher concentra-
tions of SSZ were required to inhibit TNFa production in
CEM/SSZ cells than in CEM (T) cells (fig 3A).
Mechanistically this might be consistent with the fact that
after PMA/ionomycin stimulation the activation and nuclear
translocation of NFkB in CEM/SSZ cells is less effectively
inhibited by SSZ6 7 36 because of drug efflux via ABCG2.
Consequently, TNFa production is less inhibited than in CEM
(T) cells. Besides differences in the potency of SSZ to inhibit
TNFa production, it is important to recognise that after PMA/
ionomycin stimulation, basal levels of TNFa production were
two- to threefold higher in CEM/SSZ cells than in CEM (T)
cells. This may indicate that induction of SSZ resistance is
associated with alterations in the NFkB signalling pathway
that controls the transcription of anti-apoptotic and proin-
flammatory cytokine/chemokine genes.53–55
In contrast with the up regulated expression of ABCG2/
BCRP in CEM/SSZ cells, we noted a down regulated
expression of another drug efflux pump MRP1 (fig 2A).
MRP1 has an established role in exporting hydrophobic and
hydrophilic drugs, the latter often as glutathione conju-
gates.21 22 Immunologically, MRP1 has an important function
in dendritic cells by exporting the cysteinyl leucotriene LTC4,
which mediates the signalling for chemokine CCL19 chemo-
taxis and migration of dendritic cells to the lymph nodes.56
Because SSZ has been reported to inhibit LTC synthetase,57
this may suggest that a diminished LTC production coincides
with a lowered expression of the LTC4 transporter MRP1.
Collectively, this in vitro study illustrates that long term
exposure of human T cells to SSZ can result in up regulated
expression of the MDR pump ABCG2 and increased produc-
tion of TNFa, a key component of progressive disease in
RA.58 59 In this respect, we also noted up regulation of ABCG2
expression in human monocytic THP1 and U937 cells after in
vitro exposure to SSZ (Oerlemans R et al, unpublished
observation), suggesting that this phenomenon is also of
relevance for other inflammatory related cell types. Given the
accumulating evidence for involvement of MDR pumps in
conferring resistance to at least three DMARDs—SSZ
(ABCG2) (this study), chloroquine (MRP1),60 and metho-
trexate (MRP1, ABCG2)61 62—further research is warranted to
examine whether MDR pumps also have a role in the reduced
(preclinical and clinical) efficacy of other DMARDs after long
term treatment of patients with RA. Thus studies evaluating
inhibitors of ABCG223 25 63 as possible chemosensitisers for
SSZ activity deserve further attention.
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